{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T23:43:39Z","timestamp":1793835819062,"version":"4.6.1"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,4,15]],"date-time":"2021-04-15T00:00:00Z","timestamp":1618444800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,4,15]],"date-time":"2021-04-15T00:00:00Z","timestamp":1618444800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004361","name":"Krebsliga Schweiz","doi-asserted-by":"publisher","award":["KFS-4851-08-2019"],"award-info":[{"award-number":["KFS-4851-08-2019"]}],"id":[{"id":"10.13039\/501100004361","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004543","name":"China Scholarship Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004543","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Escape from programmed cell death is a hallmark of cancer. In this study, we investigated the anti-apoptotic mechanisms and explored the therapeutic potential of BCL-2 homology domain-3 (BH3) mimetics in malignant pleural mesothelioma (MPM), a lethal thoracic malignancy with an extreme dearth of treatment options. By implementing integrated analysis of functional genomic data of MPM cells and quantitative proteomics of patients\u2019 tumors, we identified BCL-X\n                    <jats:sub>L<\/jats:sub>\n                    as an anti-apoptotic driver that is overexpressed and confers an oncogenic dependency in MPM. MPM cells harboring genetic alterations that inactivate the NF2\/LATS1\/2 signaling are associated with increased sensitivity to A-1155463, a BCL-X\n                    <jats:sub>L<\/jats:sub>\n                    -selective BH3 mimetic. Importantly, BCL-X\n                    <jats:sub>L<\/jats:sub>\n                    inhibition elicits protective autophagy, and concomitant blockade of BCL-X\n                    <jats:sub>L<\/jats:sub>\n                    and autophagic machinery with A-1155463 and hydroxychloroquine (HCQ), the US Food and Drug Administration (FDA)-approved autophagy inhibitor, synergistically enhances anti-MPM effects in vitro and in vivo. Together, our work delineates the molecular basis underlying resistance to apoptosis and uncovers an evasive mechanism that limits response to BH3 mimetics in MPM, suggesting a novel strategy to target this aggressive disease.\n                  <\/jats:p>","DOI":"10.1038\/s41419-021-03668-x","type":"journal-article","created":{"date-parts":[[2021,4,15]],"date-time":"2021-04-15T06:30:49Z","timestamp":1618468249000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Malignant pleural mesothelioma co-opts BCL-XL and autophagy to escape apoptosis"],"prefix":"10.1038","volume":"12","author":[{"given":"Duo","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun-Qing","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8732-5910","authenticated-orcid":false,"given":"Haitang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5629-6363","authenticated-orcid":false,"given":"R\u00e9my","family":"Bruggmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Oberhaensli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5442-9791","authenticated-orcid":false,"given":"Sabina","family":"Berezowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas M.","family":"Marti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean R. R.","family":"Hall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Dorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregor J.","family":"Kocher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph A.","family":"Schmid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1199-6520","authenticated-orcid":false,"given":"Ren-Wang","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,15]]},"reference":[{"key":"3668_CR1","doi-asserted-by":"publisher","first-page":"e161","DOI":"10.1016\/S1470-2045(18)30100-1","volume":"19","author":"A Scherpereel","year":"2018","unstructured":"Scherpereel, A., Wallyn, F., Albelda, S. M. & Munck, C. Novel therapies for malignant pleural mesothelioma. Lancet Oncol. 19, e161\u2013e172 (2018).","journal-title":"Lancet Oncol."},{"key":"3668_CR2","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1158\/2159-8290.CD-18-0804","volume":"8","author":"J Hmeljak","year":"2018","unstructured":"Hmeljak, J. et al. Integrative molecular characterization of malignant pleural mesothelioma. Cancer Disco. 8, 1548\u20131565 (2018).","journal-title":"Cancer Disco."},{"key":"3668_CR3","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.lungcan.2018.11.034","volume":"127","author":"L Wu","year":"2019","unstructured":"Wu, L. et al. Progress of malignant mesothelioma research in basic science: a review of the 14th international conference of the international mesothelioma interest group (iMig2018). Lung Cancer 127, 138\u2013145 (2019).","journal-title":"Lung Cancer"},{"key":"3668_CR4","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3389\/fonc.2018.00091","volume":"8","author":"M Rossini","year":"2018","unstructured":"Rossini, M. et al. New perspectives on diagnosis and therapy of malignant pleural mesothelioma. Front. Oncol. 8, 91 (2018).","journal-title":"Front. Oncol."},{"key":"3668_CR5","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1158\/0008-5472.CAN-14-1008","volume":"75","author":"G Guo","year":"2015","unstructured":"Guo, G. et al. Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma. Cancer Res. 75, 264\u2013269 (2015).","journal-title":"Cancer Res."},{"key":"3668_CR6","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/ng.3520","volume":"48","author":"R Bueno","year":"2016","unstructured":"Bueno, R. et al. Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations. Nat. Genet. 48, 407\u2013416 (2016).","journal-title":"Nat. Genet."},{"key":"3668_CR7","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","volume":"21","author":"NJ Vogelzang","year":"2003","unstructured":"Vogelzang, N. J. et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J. Clin. Oncol. 21, 2636\u20132644 (2003).","journal-title":"J. Clin. Oncol."},{"key":"3668_CR8","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/embor.2012.11","volume":"13","author":"W Li","year":"2012","unstructured":"Li, W., Cooper, J., Karajannis, M. A. & Giancotti, F. G. Merlin: a tumour suppressor with functions at the cell cortex and in the nucleus. EMBO Rep. 13, 204\u2013215 (2012).","journal-title":"EMBO Rep."},{"key":"3668_CR9","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/j.cell.2015.10.044","volume":"163","author":"F-X Yu","year":"2015","unstructured":"Yu, F.-X., Zhao, B. & Guan, K.-L. Hippo pathway in organ size control, tissue homeostasis, and cancer. Cell 163, 811\u2013828 (2015).","journal-title":"Cell"},{"key":"3668_CR10","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1101\/gad.1938710","volume":"24","author":"S Benhamouche","year":"2010","unstructured":"Benhamouche, S. et al. Nf2\/Merlin controls progenitor homeostasis and tumorigenesis in the liver. Genes Dev. 24, 1718\u20131730 (2010).","journal-title":"Genes Dev."},{"key":"3668_CR11","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646\u2013674 (2011).","journal-title":"Cell"},{"key":"3668_CR12","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/j.ccell.2018.11.004","volume":"34","author":"D Merino","year":"2018","unstructured":"Merino, D. et al. BH3-mimetic drugs: blazing the trail for new cancer medicines. Cancer Cell 34, 879\u2013891 (2018).","journal-title":"Cancer Cell"},{"key":"3668_CR13","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1038\/nrc1736","volume":"5","author":"SW Fesik","year":"2005","unstructured":"Fesik, S. W. Promoting apoptosis as a strategy for cancer drug discovery. Nat. Rev. Cancer 5, 876\u2013885 (2005).","journal-title":"Nat. Rev. Cancer"},{"key":"3668_CR14","doi-asserted-by":"publisher","first-page":"279ra240","DOI":"10.1126\/scitranslmed.aaa4642","volume":"7","author":"JD Leverson","year":"2015","unstructured":"Leverson, J. D. et al. Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy. Sci. Transl. Med. 7, 279ra240 (2015).","journal-title":"Sci. Transl. Med."},{"key":"3668_CR15","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1016\/S1470-2045(16)30019-5","volume":"17","author":"S Stilgenbauer","year":"2016","unstructured":"Stilgenbauer, S. et al. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Lancet Oncol. 17, 768\u2013778 (2016).","journal-title":"Lancet Oncol."},{"key":"3668_CR16","doi-asserted-by":"publisher","first-page":"2050","DOI":"10.1172\/JCI119010","volume":"98","author":"VC Broaddus","year":"1996","unstructured":"Broaddus, V. C., Yang, L., Scavo, L. M., Ernst, J. D. & Boylan, A. M. Asbestos induces apoptosis of human and rabbit pleural mesothelial cells via reactive oxygen species. J. Clin. Invest. 98, 2050\u20132059 (1996).","journal-title":"J. Clin. Invest."},{"key":"3668_CR17","first-page":"3508","volume":"5","author":"Y Soini","year":"1999","unstructured":"Soini, Y. et al. Apoptosis and expression of apoptosis regulating proteins bcl-2, mcl-1, bcl-X, and bax in malignant mesothelioma. Clin. Cancer Res. 5, 3508\u20133515 (1999).","journal-title":"Clin. Cancer Res"},{"key":"3668_CR18","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/s41416-018-0145-3","volume":"119","author":"D Xu","year":"2018","unstructured":"Xu, D. et al. Increased sensitivity to apoptosis upon endoplasmic reticulum stress-induced activation of the unfolded protein response in chemotherapy-resistant malignant pleural mesothelioma. Br. J. Cancer 119, 65\u201375 (2018).","journal-title":"Br. J. Cancer"},{"key":"3668_CR19","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1038\/sj.bjc.6605184","volume":"101","author":"BA Jacobson","year":"2009","unstructured":"Jacobson, B. A. et al. Activated 4E-BP1 represses tumourigenesis and IGF-I-mediated activation of the eIF4F complex in mesothelioma. Br. J. Cancer 101, 424\u2013431 (2009).","journal-title":"Br. J. Cancer"},{"key":"3668_CR20","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.3390\/cancers11101502","volume":"11","author":"D Xu","year":"2019","unstructured":"Xu, D. et al. Endoplasmic reticulum stress signaling as a therapeutic target in malignant pleural mesothelioma. Cancers 11, 1502 (2019).","journal-title":"Cancers"},{"key":"3668_CR21","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","volume":"70","author":"TC Chou","year":"2010","unstructured":"Chou, T. C. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 70, 440\u2013446 (2010).","journal-title":"Cancer Res"},{"key":"3668_CR22","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1158\/1535-7163.MCT-19-0724","volume":"19","author":"D Xu","year":"2020","unstructured":"Xu, D. et al. CRISPR screening identifies WEE1 as a combination target for standard chemotherapy in malignant pleural mesothelioma. Mol. Cancer Ther. 19, 661\u2013672 (2020).","journal-title":"Mol. Cancer Ther."},{"key":"3668_CR23","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/nmeth.2089","volume":"9","author":"CA Schneider","year":"2012","unstructured":"Schneider, C. A., Rasband, W. S. & Eliceiri, K. W. NIH image to ImageJ: 25 years of image analysis. Nat. Methods 9, 671\u2013675 (2012).","journal-title":"Nat. Methods"},{"key":"3668_CR24","doi-asserted-by":"publisher","first-page":"2481","DOI":"10.4081\/ejh.2015.2481","volume":"59","author":"AM Schlafli","year":"2015","unstructured":"Schlafli, A. M., Berezowska, S., Adams, O., Langer, R. & Tschan, M. P. Reliable LC3 and p62 autophagy marker detection in formalin fixed paraffin embedded human tissue by immunohistochemistry. Eur. J. Histochem. 59, 2481 (2015).","journal-title":"Eur. J. Histochem."},{"key":"3668_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-17204-5","volume":"7","author":"P Bankhead","year":"2017","unstructured":"Bankhead, P. et al. QuPath: open source software for digital pathology image analysis. Sci. Rep. 7, 16878 (2017).","journal-title":"Sci. Rep."},{"key":"3668_CR26","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/978-1-4939-9585-1_17","volume":"2019","author":"S Parejo","year":"2019","unstructured":"Parejo, S. et al. Assessing autophagy during retinoid treatment of breast cancer cells. Methods Mol. Biol. 2019, 237\u2013256 (2019).","journal-title":"Methods Mol. Biol."},{"key":"3668_CR27","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1038\/s41591-019-0367-9","volume":"25","author":"CG Kinsey","year":"2019","unstructured":"Kinsey, C. G. et al. Protective autophagy elicited by RAF->MEK->ERK inhibition suggests a treatment strategy for RAS-driven cancers. Nat. Med. 25, 620\u2013627 (2019).","journal-title":"Nat. Med."},{"key":"3668_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41389-019-0158-7","volume":"8","author":"H Yang","year":"2019","unstructured":"Yang, H. et al. HSP90\/AXL\/eIF4E-regulated unfolded protein response as an acquired vulnerability in drug-resistant KRAS-mutant lung cancer. Oncogenesis 8, 45 (2019).","journal-title":"Oncogenesis"},{"key":"3668_CR29","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1038\/nmeth.2650","volume":"10","author":"J Li","year":"2013","unstructured":"Li, J. et al. TCPA: a resource for cancer functional proteomics data. Nat. Methods 10, 1046\u20131047 (2013).","journal-title":"Nat. Methods"},{"key":"3668_CR30","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami, E. et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Disco. 2, 401\u2013404 (2012).","journal-title":"Cancer Disco."},{"key":"3668_CR31","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.cell.2017.06.010","volume":"170","author":"A Tsherniak","year":"2017","unstructured":"Tsherniak, A. et al. Defining a cancer dependency map. Cell 170, 564\u2013576 (2017). e516.","journal-title":"Cell"},{"key":"3668_CR32","doi-asserted-by":"publisher","first-page":"D991","DOI":"10.1093\/nar\/gks1193","volume":"41","author":"T Barrett","year":"2012","unstructured":"Barrett, T. et al. NCBI GEO: archive for functional genomics data sets\u2014update. Nucleic Acids Res. 41, D991\u2013D995 (2012).","journal-title":"Nucleic Acids Res."},{"key":"3668_CR33","doi-asserted-by":"publisher","first-page":"D955","DOI":"10.1093\/nar\/gks1111","volume":"41","author":"W Yang","year":"2013","unstructured":"Yang, W. et al. Genomics of drug sensitivity in cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res. 41, D955\u2013D961 (2013).","journal-title":"Nucleic Acids Res"},{"key":"3668_CR34","doi-asserted-by":"publisher","first-page":"D941","DOI":"10.1093\/nar\/gky1015","volume":"47","author":"JG Tate","year":"2019","unstructured":"Tate, J. G. et al. COSMIC: the catalogue of somatic mutations in cancer. Nucleic Acids Res. 47, D941\u2013D947 (2019).","journal-title":"Nucleic Acids Res."},{"key":"3668_CR35","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/nrc3538","volume":"13","author":"P Juin","year":"2013","unstructured":"Juin, P., Geneste, O., Gautier, F., Depil, S. & Campone, M. Decoding and unlocking the BCL-2 dependency of cancer cells. Nat. Rev. Cancer 13, 455\u2013465 (2013).","journal-title":"Nat. Rev. Cancer"},{"key":"3668_CR36","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/cdd.2017.183","volume":"25","author":"J Montero","year":"2018","unstructured":"Montero, J. & Letai, A. Why do BCL-2 inhibitors work and where should we use them in the clinic? Cell Death Differ. 25, 56\u201364 (2018).","journal-title":"Cell Death Differ."},{"key":"3668_CR37","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.ccr.2006.03.027","volume":"9","author":"M Certo","year":"2006","unstructured":"Certo, M. et al. Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell 9, 351\u2013365 (2006).","journal-title":"Cancer Cell"},{"key":"3668_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/15548627.2015.1100356","volume":"12","author":"DJ Klionsky","year":"2016","unstructured":"Klionsky, D. J. et al. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy 12, 1\u2013222 (2016).","journal-title":"Autophagy"},{"key":"3668_CR39","doi-asserted-by":"publisher","first-page":"856","DOI":"10.15252\/embj.201490784","volume":"34","author":"L Galluzzi","year":"2015","unstructured":"Galluzzi, L. et al. Autophagy in malignant transformation and cancer progression. EMBO J. 34, 856\u2013880 (2015).","journal-title":"EMBO J."},{"key":"3668_CR40","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1038\/bjc.2014.355","volume":"111","author":"JL Liu","year":"2014","unstructured":"Liu, J. L. et al. Prognostic significance of p62\/SQSTM1 subcellular localization and LC3B in oral squamous cell carcinoma. Br. J. Cancer 111, 944\u2013954 (2014).","journal-title":"Br. J. Cancer"},{"key":"3668_CR41","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1080\/15548627.2016.1173799","volume":"12","author":"C Follo","year":"2016","unstructured":"Follo, C., Barbone, D., Richards, W. G., Bueno, R. & Broaddus, V. C. Autophagy initiation correlates with the autophagic flux in 3D models of mesothelioma and with patient outcome. Autophagy 12, 1180\u20131194 (2016).","journal-title":"Autophagy"},{"key":"3668_CR42","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.drup.2007.08.002","volume":"10","author":"L Zhang","year":"2007","unstructured":"Zhang, L., Ming, L. & Yu, J. BH3 mimetics to improve cancer therapy; mechanisms and examples. Drug Resist. Updat. 10, 207\u2013217 (2007).","journal-title":"Drug Resist. Updat"},{"key":"3668_CR43","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/S1470-2045(04)01492-5","volume":"5","author":"DA Fennell","year":"2004","unstructured":"Fennell, D. A. & Rudd, R. M. Defective core-apoptosis signalling in diffuse malignant pleural mesothelioma: opportunities for effective drug development. Lancet Oncol. 5, 354\u2013362 (2004).","journal-title":"Lancet Oncol."},{"key":"3668_CR44","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1038\/sj.cgt.7700332","volume":"8","author":"I Mohiuddin","year":"2001","unstructured":"Mohiuddin, I., Cao, X., Fang, B., Nishizaki, M. & Smythe, W. R. Significant augmentation of pro-apoptotic gene therapy by pharmacologic bcl-xl down-regulation in mesothelioma. Cancer Gene Ther. 8, 547\u2013554 (2001).","journal-title":"Cancer Gene Ther."},{"key":"3668_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2011.58","volume":"2","author":"D Barbone","year":"2011","unstructured":"Barbone, D. et al. The Bcl-2 repertoire of mesothelioma spheroids underlies acquired apoptotic multicellular resistance. Cell Death Dis. 2, e174 (2011).","journal-title":"Cell Death Dis."},{"key":"3668_CR46","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-12-42","volume":"12","author":"X Cao","year":"2013","unstructured":"Cao, X. et al. The novel BH3 alpha-helix mimetic JY-1-106 induces apoptosis in a subset of cancer cells (lung cancer, colon cancer and mesothelioma) by disrupting Bcl-xL and Mcl-1 protein-protein interactions with Bak. Mol. Cancer 12, 42 (2013).","journal-title":"Mol. Cancer"},{"key":"3668_CR47","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1158\/2159-8290.CD-13-0315","volume":"4","author":"AC Faber","year":"2014","unstructured":"Faber, A. C. et al. mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2\/BCL-XL inhibition by suppressing MCL-1. Cancer Disco. 4, 42\u201352 (2014).","journal-title":"Cancer Disco."},{"key":"3668_CR48","doi-asserted-by":"publisher","first-page":"2661","DOI":"10.1111\/febs.13472","volume":"283","author":"JT Opferman","year":"2016","unstructured":"Opferman, J. T. Attacking cancer\u2019s Achilles heel: antagonism of anti-apoptotic BCL-2 family members. FEBS J. 283, 2661\u20132675 (2016).","journal-title":"FEBS J."},{"key":"3668_CR49","doi-asserted-by":"publisher","first-page":"7558","DOI":"10.1158\/1078-0432.CCR-17-1231","volume":"23","author":"A Budhraja","year":"2017","unstructured":"Budhraja, A. et al. Modulation of navitoclax sensitivity by dihydroartemisinin-mediated MCL-1 repression in BCR-ABL(+) B-lineage acute lymphoblastic leukemia. Clin. Cancer Res. 23, 7558\u20137568 (2017).","journal-title":"Clin. Cancer Res."},{"key":"3668_CR50","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1002\/ijc.11209","volume":"106","author":"S Hopkins-Donaldson","year":"2003","unstructured":"Hopkins-Donaldson, S. et al. Induction of apoptosis and chemosensitization of mesothelioma cells by Bcl-2 and Bcl-xL antisense treatment. Int. J. Cancer 106, 160\u2013166 (2003).","journal-title":"Int. J. Cancer"},{"key":"3668_CR51","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1016\/j.ijrobp.2019.11.029","volume":"106","author":"MR Jackson","year":"2020","unstructured":"Jackson, M. R. et al. Mesothelioma cells depend on the antiapoptotic protein Bcl-xL for survival and are sensitized to ionizing radiation by BH3-mimetics. Int. J. Radiat. Oncol. Biol. Phys. 106, 867\u2013877 (2020).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"3668_CR52","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/s41418-017-0012-4","volume":"25","author":"L Galluzzi","year":"2018","unstructured":"Galluzzi, L. et al. Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. Cell Death Differ. 25, 486\u2013541 (2018).","journal-title":"Cell Death Differ."},{"key":"3668_CR53","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1038\/nrm2239","volume":"8","author":"MC Maiuri","year":"2007","unstructured":"Maiuri, M. C., Zalckvar, E., Kimchi, A. & Kroemer, G. Self-eating and self-killing: crosstalk between autophagy and apoptosis. Nat. Rev. Mol. Cell Biol. 8, 741\u2013752 (2007).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"3668_CR54","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/nrm3735","volume":"15","author":"G Marino","year":"2014","unstructured":"Marino, G., Niso-Santano, M., Baehrecke, E. H. & Kroemer, G. Self-consumption: the interplay of autophagy and apoptosis. Nat. Rev. Mol. Cell Biol. 15, 81\u201394 (2014).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"3668_CR55","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.devcel.2018.02.014","volume":"44","author":"BE Fitzwalter","year":"2018","unstructured":"Fitzwalter, B. E. et al. Autophagy inhibition mediates apoptosis sensitization in cancer therapy by relieving FOXO3a turnover. Dev. Cell 44, 555\u2013565 (2018). e3.","journal-title":"Dev. Cell"},{"key":"3668_CR56","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.tcb.2011.03.007","volume":"21","author":"JM Gump","year":"2011","unstructured":"Gump, J. M. & Thorburn, A. Autophagy and apoptosis: what is the connection? Trends Cell Biol. 21, 387\u2013392 (2011).","journal-title":"Trends Cell Biol."},{"key":"3668_CR57","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1080\/15548627.2015.1017191","volume":"11","author":"JM Pedro","year":"2015","unstructured":"Pedro, J. M. et al. BAX and BAK1 are dispensable for ABT-737-induced dissociation of the BCL2-BECN1 complex and autophagy. Autophagy 11, 452\u2013459 (2015).","journal-title":"Autophagy"},{"key":"3668_CR58","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1080\/15548627.2016.1179406","volume":"12","author":"B Reljic","year":"2016","unstructured":"Reljic, B. et al. BAX-BAK1-independent LC3B lipidation by BH3 mimetics is unrelated to BH3 mimetic activity and has only minimal effects on autophagic flux. Autophagy 12, 1083\u20131093 (2016).","journal-title":"Autophagy"},{"key":"3668_CR59","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1038\/aps.2017.78","volume":"38","author":"QH Lin","year":"2017","unstructured":"Lin, Q. H. et al. ABT-263 induces G1\/G0-phase arrest, apoptosis and autophagy in human esophageal cancer cells in vitro. Acta Pharm. Sin. 38, 1632\u20131641 (2017).","journal-title":"Acta Pharm. Sin."},{"key":"3668_CR60","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1038\/s41420-020-00348-1","volume":"6","author":"S Arulananda","year":"2020","unstructured":"Arulananda, S. et al. BCL-XL is an actionable target for treatment of malignant pleural mesothelioma. Cell Death Disco. 6, 114 (2020).","journal-title":"Cell Death Disco."}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-021-03668-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-021-03668-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-021-03668-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T03:53:48Z","timestamp":1669953228000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-021-03668-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,15]]},"references-count":60,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,4]]}},"alternative-id":["3668"],"URL":"https:\/\/doi.org\/10.1038\/s41419-021-03668-x","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,15]]},"assertion":[{"value":"13 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The animal experiments were approved by the Veterinary Office of Canton Bern, Switzerland.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"406"}}